Neuropharmacological characterization of serotoninergic stimulation of vasopressin secretion in conscious rats.
In this study we have evaluated a possible role for brain serotoninergic neurons in the regulation of vasopressin secretion using pharmacological methods. In order to accomplish this, we have developed a specific and sensitive vasopressin radioimmunoassay along with a highly reproducible plasma extraction protocol. These tools were used to evaluate the plasma vasopressin response to several pharmacological challenges in conscious rats. Treatment with the serotonin (5-HT) releaser p-chloroamphetamine caused a significant increase in plasma vasopressin concentration. This effect was blocked by posterior hypothalamic deafferentation which separates serotonin cell bodies in the midbrain from their nerve terminals in the hypothalamus. Administration of graded doses of several 5-HT agonists had no effect. However, treatment with MK212, a serotonin agonist with 5-HT1 + 5-HT2 activity, induced a significant increase in plasma vasopressin concentration. The effect of MK212 on plasma vasopressin was completely abolished by the selective 5-HT2 receptor blocker LY53857. These studies confirm and extend studies by others that provide pharmacological evidence for serotoninergic regulation of vasopressin secretion via a selective 5-HT2 receptor mechanism. The specific neuroanatomical site(s) where serotonin exerts this effect are unknown, and the physiological consequences of these studies remain to be established.
Brownfield
M S
MS
Department of Comparative Biosciences, School of Veterinary Medicine, University of Wisconsin, Madison.
Greathouse
J
J
Lorens
S A
SA
Armstrong
J
J
Urban
J H
JH
Van de Kar
L D
LD
D000662:Amphetamines / Q000494:pharmacology*; D000818:Animals; D004305:Dose-Response Relationship, Drug; D004873:Ergolines / Q000494:pharmacology; D007026:Hypothalamic Area, Lateral / Q000502:physiology*; D008297:Male; D011719:Pyrazines / Q000494:pharmacology; D011863:Radioimmunoassay; D051381:Rats; D011985:Receptors, Serotonin / Q000187:drug effects / Q000502:physiology*; D012701:Serotonin / Q000378:metabolism / Q000502:physiology*; D014667:Vasopressins / Q000097:blood*; D010133:p-Chloroamphetamine / Q000494:pharmacology*
D000662:Amphetamines; D004873:Ergolines; D011719:Pyrazines; D011985:Receptors, Serotonin; D014667:Vasopressins; D012701:Serotonin; C014896:6-chloro-2-(1-piperazinyl)pyrazine; D010133:p-Chloroamphetamine; C032663:LY 53857